$-0.28 EPS Expected for Agile Therapeutics, Inc. (AGRX) as of May, 14

April 17, 2018 - By Robert Reynolds

Agile Therapeutics, Inc. (NASDAQ:AGRX) Corporate Logo
Big Money Sentiment increased to 1.71 in Q4 2017. It has change of 0.36, from 2017Q3’s 1.35. The ratio increased due to Agile Therapeutics, Inc. positioning: 11 sold and 6 reduced. 13 funds amassed holdings and 16 increased holdings. Investors holded 23.16 million in 2017Q3 but now own 22.48 million shares or 2.92% less.
Bnp Paribas Arbitrage Sa stated it has 523 shs or 0% of all its holdings. Moreover, Bridgeway has 0% invested in Agile Therapeutics, Inc. (NASDAQ:AGRX). 24,844 are held by Deutsche Bank & Trust Ag. Falcon Point Llc holds 0.03% or 63,744 shs in its capital. Caxton, New Jersey-based fund reported 1.82M shs. Bancorporation Of Montreal Can has invested 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Alyeska Lp reported 316,399 shs or 0.01% of all its holdings. Savings Bank Of Mellon stated it has 0% in Agile Therapeutics, Inc. (NASDAQ:AGRX). Panagora Asset Management invested 0% of its capital in Agile Therapeutics, Inc. (NASDAQ:AGRX). Virtu Financial Lc holds 0.01% or 86,316 shs in its capital. Atlantic Tru Grp Lc accumulated 2,145 shs. Alpine Glob Mgmt Limited Liability Company stated it has 22,001 shs. Investor has 3.51M shs for 0.62% of their capital. Parametric Assocs Ltd Company reported 11,941 shs or 0% of all its holdings. 89,133 were reported by Dimensional Fund Advsr Ltd Partnership.

On May, 14 is anticipated Agile Therapeutics, Inc. (NASDAQ:AGRX)’s earnings report, according to RTT. EPS of $-0.28 is 7.69 % down from 2017’s $-0.26 EPS. After $-0.18 EPS was reported last quarter, analysts now see negative EPS growth of 55.56 % for Agile Therapeutics, Inc.. The stock decreased 1.36% or $0.04 during the last trading session, reaching $2.91.Agile Therapeutics, Inc. has volume of 102,882 shares. Since April 17, 2017 AGRX has declined 11.00% and is downtrending. AGRX underperformed the S&P500 by 22.55%.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Ratings Coverage

In total 5 analysts cover Agile Therapeutics (NASDAQ:AGRX). “Buy” rating has 3, “Sell” are 0, while 2 are “Hold”. 60% are bullish. 11 are the (NASDAQ:AGRX)’s analyst reports since November 6, 2017 according to StockzIntelligence Inc. In Thursday, November 9 report Noble Financial maintained the stock with “Buy” rating. In Friday, December 22 report H.C. Wainwright maintained the stock with “Buy” rating. On Friday, December 22 the firm earned “Buy” rating by Noble Financial. In Friday, December 22 report Janney Capital downgraded the stock to “Hold” rating. On Tuesday, December 26 the stock of Agile Therapeutics, Inc. (NASDAQ:AGRX) has “Hold” rating given by William Blair. In Thursday, March 29 report Cantor Fitzgerald maintained the stock with “Buy” rating. In Tuesday, March 13 report H.C. Wainwright maintained the stock with “Buy” rating. On Monday, November 20 the stock has “Buy” rating by Cantor Fitzgerald. On Friday, December 22 the firm earned “Hold” rating by William Blair. On Friday, December 22 the rating was maintained by Cantor Fitzgerald with “Buy”.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women.The firm is worth $99.66 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials.Currently it has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.